Top Dow Dividend Stocks To Invest In Right Now

Microsoft (NASDAQ: MSFT  ) can’t seem to take a hint.

Sources are telling Bloomberg that the software giant is slashing prices for hardware manufacturers making small tablets running Windows RT.

Microsoft’s scaled-back mobile operating system has been a dud since rolling out late last year. Its own Surface RT has been a flop. I saw it coming. You probably did, too.

Cutting prices for Windows RT licenses is a step in the right direction, but it doesn’t go far enough. Microsoft is competing with Google’s (NASDAQ: GOOG  ) Android and Apple’s (NASDAQ: AAPL  ) iOS, and it can’t match the ecosystem or developer support of either platform.

Folks aren’t buying Windows 8-fueled tablets in large numbers, but at least there’s some support for a device that is truly compatible with PCs. Windows RT — a costly Android wannabe that trades a lack of app selection for access to a Microsoft Office workaround — just isn’t selling at all.

Top Dow Dividend Stocks To Invest In Right Now: Xueda Education Group(XUE)

Xueda Education Group provides tutoring services for primary and secondary school students in the People?s Republic of China with a focus on offering personalized tutoring services. Its services include consultation and assessment, formulation of a customized study plan, personalized tutoring, and delivery of supporting services. The company also provides course offerings that cover various academic subjects taught in primary and secondary schools, such as mathematics, English, physics, Chinese, and chemistry; and self-designed courses beyond the standard curriculum in certain subjects, as well as in subjects not taught at public primary and secondary schools. As of December 31, 2010, its tutoring service network comprised 207 learning centers and approximately 9,650 full-time service professionals, serving customers located in 53 economically developed cities across 27 of China?s 31 provinces and municipalities. The company was founded in 2001 and is headquartered in Beij ing, the People?s Republic of China.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Leading and Lagging Sectors
    In trading on Friday, non-cyclical consumer goods & services shares were relative leaders, up on the day by about 0.09 percent. Among the leading sector stocks, gains came from Rite Aid (NYSE: RAD) and Xueda Education Group (NYSE: XUE). Financial sector was the leading decliner in the US market today.

Top Dow Dividend Stocks To Invest In Right Now: Corelogic Inc (CLGX)

CoreLogic, Inc. (CoreLogic),incorporated on October 13, 2009, is a provider of property information, analytics and services provider in the United States of America and Australia. The Company provides detailed coverage of property, mortgages and other encumbrances, consumer credit, tenancy, location, hazard risk and related performance information. The markets the Company serves include real estate and mortgage finances, insurance, capital markets and government. The Company offers its customers databases of public, contributory data covering real property and mortgages information, judgments and liens, parcel and geospatial data, criminal background records, national coverage eviction information, non-prime lending records, credit information, and tax information, among other data types. It serves its customers’ needs for mortgage and automotive credit reporting, property tax, property valuation, flood plain location determination and other geospatial data, data, analytic s and related services. The Company operates in three segments: data and analytics, mortgage origination services and asset management and processing solutions.

Data and Analytics

The Company’s data and analytics segment offers access to data assets including real estate information, such as property characteristic information, mortgage information, collateral information, and images of publicly recorded documents relating to real property, mortgage-backed securities information, criminal and eviction records, employment verification, flood and hazard information and under-banked credit information. The Company licenses its data directly to its customers and provide its customers with analytical products and services for risk management, collateral assessment and fraud prediction. The Company also provides consumer screening and risks management for the multi-family housing and under-banked credit services industries. The Company’s primary custome rs are commercial banks, mortgage lenders and brokers, inves! tment banks, fixed-income investors, real estate agents, property and casualty insurance companies, title insurance companies, property management companies and government-sponsored enterprises.

The Company is a provider of fraud detection, collateral and mortgages performance analytics and real estate and mortgage-backed securities information. The Company uses its data to link property location and characteristics , real estate transactions and consumer and loans information to provide useful insights and analysis for its customers. The Company’s customers span many industries, including mortgage lending, government, capital markets, consumer-direct, property and casualty insurance, direct marketing, utilities and retail. The Company obtains, normalizes and aggregates real estate property and loans data and make such data available to its customers with a standard format over the Web or in bulk data form. In addition, the Company offers a number of other servi ces that help its customers make risk assessments, determine property values and track market performance. The Company offers its customers a host of property valuation services in an effort to assist them in assessing their risk of loss with alternative forms of property valuations, depending upon their needs and regulatory requirements. These include, among others, automated valuation models collateral risk scores, appraisal review services and valuation reconciliation services.

The Company provides solutions designed to assist its customers in detecting and preventing mortgage fraud and managing risk. The Company also provides advisory services that allow holders of mortgage-backed securities, loan and real property portfolios to gain insight on the value, quality and attributes of those assets. The Company provides document retrieval, custom fulfillment, advisory and other services that allows its customers to benefit from its specialists and their knowledge of its data to provide project-based or client-customized r! eports. T! he Company is a provider of screening and risks management services for the multi-family housing industry. The Company conducts applicant screening and generate consumer reports containing information that may includes landlord-tenant court records, lease and payment performance history, credit history and criminal records history primarily for residential property managers and owners throughout the United States.

The Company is a provider of natural hazard risk management and information solutions with premium locational accuracy and spatial datasets. The Company also offers specialized data and analytical models including Wildfire Risk Score, Coastal Risk Score, Flood Risk Score, Earthquake and Fire Protection Class. The Company’s analytics and hazard data are delivered to customers through multiple methods including the RiskMeter Online platform, a software as a service platform targeted to insurance industry participants. The Company is a provider of credit reports for under-banked consumer and specialty borrowers. The Company’s customers range in size from single proprietorships to major credit card issuers. The Company is a provider of real estate listing software systems.

Mortgage Origination Services

The Company provides loan origination and closing-related services and solutions to mortgages originators, including tax services and flood and data services. The segment’s primary customers are national mortgage lenders and servicers, but the Company also serves regional mortgage lenders and brokers, credit unions, commercial banks, government agencies and property and casualty insurance companies.

The Company provides property tax services in the United States. The Company procures and aggregates property taxes information from over 20,000 taxing authorities. The Company uses this information to advise mortgage originators and servicers of the property taxes payment status on their lo ans and to monitor that status for the life of the loans. Th! e Company! also may indemnify mortgage lenders against losses for any failure to make transfers to taxing authorities.

The Company provides flood zone determinations in the United States. The Company typically furnishes a mortgage originator or servicer with a report as to whether a property lies within a governmentally delineated flood hazard area and then monitor the property for flood hazard status changes for as long as the loan is active.

The Company provides credit services in the United States mortgage and transportation markets, with solutions that helps its customers meet their lending, leasing and other consumer credit automation needs. The Company provides cloud computing-based lending solutions to the financial services market through a comprehensive suite of enterprise lending automation solutions.

Asset Management and Processing Solutions

The Company provides analytical and outsourcing services primarily relating to de faulting and foreclosed mortgages loans to mortgage servicers, financial institutions, government and governmental-sponsored enterprises and other companies. The Company inspects , preserves, maintain and , where required, registers vacant properties with local authorities on behalf of its mortgage servicer customers.

The Company through its business processing outsourcing (BPO) offers mortgage servicers and investors a alternative to traditional appraisals. The Company provides outsourcing services to residential mortgage servicers. The Company’s processing competencies provide the servicers operational, audit and quality control services throughout the default cycle, from collections to foreclosure. The Company provides property recovery services, including eviction logistics. The Company values the asset using one or more of its full range of valuation products. The Company also offers marketing and closing services. The Company provides mortgage servicers wi th a suite of hosted default management servicing applicatio! ns. The C! ompany’s component-based solution provides modules for loss mitigation, foreclosure, bankruptcy, collateral valuations, property preservation, REO asset management and claims processing.

The Company competes with Equifax Inc., Lexis-Nexis, Lender Processing Services, Inc, TransUnion Corp., Verisk Analytics, Safeguard Properties,, Inc, and Experian plc.

Advisors’ Opinion:


    I came to this conclusion courtesy of another housing stat. Data provider CoreLogic Inc. (NYSE: CLGX) says average housing prices rose 11% in March compared with the same month in 2013.


    I came to this conclusion courtesy of another housing stat. Data provider CoreLogic Inc. (NYSE: CLGX) says average housing prices rose 11% in March compared with the same month in 2013.

Top Dow Dividend Stocks To Invest In Right Now: American Axle & Manufacturing Holdings Inc. (AXL)

American Axle & Manufacturing Holdings, Inc., together with its subsidiaries, engages in the manufacture, engineering, design, and validation of driveline and drivetrain systems, and related components and chassis modules for automotive industry in the United States. The company?s driveline and drivetrain systems comprise components that transfer power from the transmission and deliver it to the drive wheels. These products include axles, chassis modules, driveshafts, power transfer units, transfer cases, chassis and steering components, driving heads, crankshafts, transmission parts, and metal-formed products. It offers products for light trucks, sport utility vehicles, passenger cars, crossover vehicles, and commercial vehicles. The company was founded in 1994 and is headquartered in Detroit, Michigan.

Advisors’ Opinion:

  • [By Ben Levisohn]

    This week we’re awaiting a court decision on whether GM might be ordered to issue a “park it” order for recalled vehicles awaiting an ignition fix. A negative ruling would mark another escalation. A more positive headline could emerge in late-Apr/early-May if GM were to take further steps to address impacted customers (i.e. fund). The headlines stemming from GM’s internal investigation are less predictable but also present a risk. Separately, if GM normalizes ATPs, some press reports may report it negatively as we’ve seen all year. Tactically, our prior buy-on-weakness approach for GM, Ford and [American Axle & Manufacturing (AXL)] appeared to work last week and this remains our strategy as the situation unfolds.

  • [By Ben Levisohn]

    Weekend news likely prompts a negative reaction Monday, but Tues-Wed could go either way. GM stock could respond well if March share meets/beats expectations and if GM were to make adequate statements explaining concerns and offering remedies (OnStar can play role here). A sub-17% share and/or more negative revelations could pressure the stock further. We enter the week with a buy-on-weakness approach but acknowledge that this latest escalation adds ST market share risk. Thus, we also look to add positions in Buy-rated Ford (F) (possible ST share gains) and [American Axle & Manufacturing (AXL)] (pulled back + Q2 schedules appear intact).

Top Dow Dividend Stocks To Invest In Right Now: Lennar Corp.(LEN)

The third largest U.S. homebuilder by revenue reported exceptional Q3 results, as its earnings more than quadrupled, primarily as a result of an increase in new-home demand. The reported net income of 40c was well ahead of last year’s 11c, and the forecasted 28c.

According to the company’s CEO, Stuart Miller, "The homebuilding business is beginning to revert to normal, and that’s a positive for the U.S. economy in general, which is in turn good for sustained recovery in the housing market. Overall demand has been improving and we’ve seen a consistent sales pace at improving prices."

LEN’s contract backlog, which is an indicator of future sales, rose by a whopping 79% on a YoY basis. Its average selling price of delivered homes also increased to $258,000 from last year’s $247,000.

Advisors’ Opinion:

  • [By Melvin Backman]

    A handful of other homebuilder stocks are also seeing some small gains as well, including D.R. Horton (DHI), Lennar (LEN) and PulteGroup (PHM).

    Airline companies continue to soar: Delta Airlines (DAL, Fortune 500)ended the day 2% higher. It continues to be one of the top performers in the S&P 500 this year. Delta recently announced more routes in and out of Seattle as it grows it presence there, going head-to-head in the “Battle for Seattle” with Alaska Air. Southwest Airlines (LUV, Fortune 500) is also up more than 2% today.

  • [By Ben Levisohn]

    Shares of Toll Brothers have gained 1.9% to $36.32 at 11:59 a.m., but its strength hasn’t really translated into big days for other home builders. KB Home (KBH) has gained 0.4% to $16.65, DR Horton (DHI) has risen 0.4% to $23.22 and Lennar (LEN) has dipped 0.3% to $40.37.


    Patrick T. Fallon/Bloomberg via Getty Images Toll Brothers’ quarterly profit more than doubled as a recovering housing market allowed the largest U.S. luxury homebuilder to sell more homes at higher prices, sending its shares up 4 percent. The company, which sells homes that can cost more than $2 million, has been able to perform better during the past few quarters than most large U.S. homebuilders as its buyers were less affected by a recent rise in mortgage rates. Toll’s average selling price rose about 22 percent to $706,000 in the second quarter ended April 30 — a period well into the spring selling season, which is to homebuilders what the holiday shopping season is to retailers. Toll (TOL), which mainly builds single-family houses, handed over 1,218 homes in the quarter, up 36 percent from a year earlier. While the company’s sales remain strong, it decided last year to build and rent apartments to cater to the demand for rentals as higher interest rates and slow income growth pushes home ownership out of reach for many Americans. Permits to build multifamily housing such as apartment blocks rose 19.5 percent in the United States last month, compared with a 0.3 percent rise in permits for single-family homes. Toll Brothers said Wednesday it had about 1,500 rental units under construction and that it controlled sites for another 3,800. Lennar (LEN), the second-largest U.S. homebuilder, is the only other builder that is offering apartment rental units. ‘Impressive Results’ Toll’s net income soared to $65.2 million, or 35 cents a share, in the second quarter from $24.7 million, or 14 cents a share, a year earlier. Revenue jumped 67 percent to $860.4 million. Orders stayed almost flat at 1,749 homes, compared with a 6 percent fall in the first quarter. “We are in a leveling period in the early stages of the housing recovery with significant pent-up demand building,” Chief Executive Officer Douglas Yearley said in a statement. UBS analyst Davi


    Records fell on Wall Street Friday as another solid report on housing lifted the market for the second day in a row. There’s a three-day weekend coming up — something that often prompts investor caution — but the gains were broad-based even though volume was fairly light. The VIX, which measures volatility, fell to its lowest level this year. The Dow Jones industrial average (^DJI) gained 63 points, the Nasdaq composite (^IXIC) rose 31, and the Standard & Poor’s 500 index (^GPSC) added 8, topping the record high set last week. The Dow Transportation average also raced to an all-time high, lifted by airline stocks. United (UAL) soared more than 4 percent; Delta (DAL) gained more than 1 percent and Southwest (LUV) gained 2 percent. Southwest is at an all-time high, up 79 percent from a year ago. New home sales bounced back with a better than expected 6.4 percent increase last month. Lennar (LEN) and D.R. Horton (DHI) both rose 4 percent. Pulte (PHM), Beazer (BZH) and Hovnanian (HOV) also solid posted gains. Earnings continue to drive retail stocks. Gap (GPS) edged higher even though net fell. Foot Locker (FL) gained 1½ percent after topping expectations. GameStop (GME) rose 4 percent. Its net rose, helped by the rollout last year of new Xbox and PlayStation consoles. Zumiez (ZUMZ) rose 5½ percent on an earnings beat. But Aeropostale (ARO) tumbled 24 percent. Its loss widened and sales declined. The retailer continues to struggle with teen fashion trends. Also on the earnings front, TiVo (TIVO) rose 2 percent as it swung to a profit from a year ago loss. It also reported an increase in the number of subscribers. Hewlett-Packard (HPQ) rose 6 percent on news the company plans to eliminate up to 16,000 additional workers in an effort to cut costs. And several stocks extended big moves from yesterday. Best Buy (BBY) rose more than 3 percent for the second straight day after earnings beat expectations. Isis Pharmaceuticals (ISIS) jumped

Top Dow Dividend Stocks To Invest In Right Now: Cenovus Energy Inc (CVE)

Cenovus Energy, Inc. (Cenovus), incorporated on January 1, 2011, is a Canadian integrated oil company. The Company’s operations include oil sands projects in northern Alberta, which use specialized methods to drill and pump the oil to the surface. It also has natural gas and oil production in Alberta and Saskatchewan. It operates in four segments: oil sands, conventional, refining and marketing, and corporate and eliminations. The Company has 50% ownership with Phillips 66 in two United States refineries, which includes Wood River (Illinois) and Borger (Texas) refineries. It has two producing steam-assisted gravity drainage (SAGD) projects in the oil sands-Foster Creek and Christina Lake, as well as several emerging projects which are in various stages of development. Foster Creek and Christina Lake are 50%-owned by ConocoPhillips. It also produces heavy oil from the mobile Wabiskaw formation at its 100%-owned Pelican Lake operation in the Greater Pelican Region, about 3 00 kilometers north of Edmonton.

Its reserves and production are located in Canada, primarily within the provinces of Alberta and Saskatchewan. As of December 31, 2012, it had a land base of approximately seven million net acres and Company Interest Before Royalties proved reserves of approximately 1,717 million barrels of bitumen, 184 million barrels of heavy crude oil, 115 million barrels of light and medium crude oil and NGLs and 955 billion cubic feet of natural gas. It also had Company Interest Before Royalties probable reserves of approximately 676 million barrels of bitumen, 105 million barrels of heavy crude oil, 56 million barrels of light and medium crude oil and natural gas liquefied (NGLs) and 338 billion cubic feet of natural gas as of December 31, 2012.

Oil Sands

The Oil sands segment includes the development and production of Cenovus’s bitumen assets at Foster Creek, Christina Lake and Narrows Lake, as well as heavy oil assets at Pelican Lake. This segment also includes the Atha! basca natural gas assets and projects in the early stages of development, such as Grand Rapids and Telephone Lake. Certain of the Company’s operated oil sands properties, notably Foster Creek, Christina Lake and Narrows Lake, are jointly owned with ConocoPhillips. As of December 31, 2012, it had bitumen rights of approximately 1,469,000 gross acres (1,097,000 net acres) within the Athabasca and Cold Lake areas, as well as the exclusive rights to lease an additional 478,000 net acres areas on the Cold Lake Air Weapons Range on its behalf and/or its assignee’s behalf.

As of December 31, 2012, there were 56 wells producing. It operates an 80 megawatt natural gas-fired cogeneration facility in conjunction with the SAGD operation at Foster Creek. The steam and power generated by the facility is presently being used within the SAGD operation and the excess power generated is being sold into the Alberta Power Pool. It has 50% interest in Christina Lake, an oil sand s property in northeast Alberta that uses SAGD technology and produces from the McMurray formation. During 2011, the Company drilled three wells at Christina Lake using its Wedge WellTM technology. As of December 31, 2012, there were six producing wells.

The Company holds 50% interest in Narrows Lake, an oil sands property within the Christina Lake Region in northeast Alberta. The project includes gross production capacity of 130,000 barrels per day (bbls/d) of bitumen to be developed in up to three phases, with the first phase expected to have production capacity of approximately 45,000 barrels per day of bitumen. Using a pattern, horizontal well polymer flood, it produces heavy crude oil from the Cretaceous Wabiskaw formation at its Pelican Lake property, which is located within the Greater Pelican Region in northeast Alberta. During 2012, it drilled 76 heavy oil wells. The Company holds a 38% non-operated interest in 110 kilometers, 20-inch diameter crude oil pipeline, which connects the Pelican Lake area to a pipelin! e that tr! ansports crude oil from northern Alberta to crude oil markets.

The Company’s new resource play assets include oil sands properties. Its Grand Rapids property is located in the Greater Pelican Region in northeast Alberta, where deposits of bitumen have been identified in the Cretaceous Grand Rapids formation. Its Telephone Lake property is located in the Borealis Region in northeast Alberta. The Steepbank and East McMurray properties are also located in the Borealis Region, southwest of Telephone Lake. It produces natural gas from the Cold Lake Air Weapons Range and several surrounding landholdings located in northeast Alberta and hold surface access and natural gas rights for exploration, development and transportation from areas. The majority of its natural gas production in the area is processed through wholly owned and operated compression facilities.


Conventional segment includes the development and production of conv entional crude oil, NGLs and natural gas in Alberta and Saskatchewan. It includes the carbon dioxide enhanced oil recovery project at Weyburn and emerging tight oil opportunities. As of December 31, 2012, it had an established land position of approximately 4.9 million gross acres, of which approximately 3.2 million gross acres are developed. The mineral rights on approximately 59% of its net landholdings are owned in fee title by Cenovus. It leases Crown lands in some areas in Alberta, mainly in the Early Cretaceous geological formations, primarily in the Suffield and Wainwright areas.

The Company holds interests in multiple zones in the Suffield, Brooks North, Langevin, Drumheller, and Wainwright areas in southern Alberta with a mix of medium and heavy crude oil production. Development in these areas focuses on infill drilling, optimization of existing wells and other specialized oil recovery methods. It operates water handling facilities to manage oil product ion. In the unitized portion of the Weyburn crude oil field ! in southe! ast Saskatchewan, it has 62% working interest. The Weyburn unit produces light and medium sour crude oil from the Mississippian Midale formation and covers 78 sections of land. As of December 31, 2012, approximately 90% of the approved CO2 flood pattern development at the Weyburn unit was completed. It holds interests in multiple zones in the Suffield, Brooks North, Langevin and Drumheller areas in southern Alberta.

Refining and Marketing

Refining and marketing segment is focused on the refining of crude oil products into petroleum and chemical products at two refineries located in the United States. The refineries are jointly owned with and operated by Phillips 66. This segment also markets Cenovus’s crude oil and natural gas, as well as third-party purchases and sales of product that provide operational flexibility for transportation commitments, product type, delivery points and customer diversification.

Through WRB Refining LP (WR B), the Company has 50% ownership interest in both the Wood River and Borger Refineries located in Roxana, Illinois and Borger, Texas respectively. ConocoPhillips is the operator and manager of WRB. As of December 31, 2012, the Wood River refinery had a processing capacity of approximately 306,000 barrels per day of crude oil, including approximately 110,000 barrels per day of heavy crude oil. It processes light low-sulphur and heavy high-sulphur crude oil that it receives from North American crude oil pipelines to produce gasoline, diesel and jet fuel, petrochemical feedstocks and asphalt. As December 31, 2012, the Borger Refinery had a processing capacity of approximately 146,000 barrels per day of crude oil, including approximately 35,000 barrels per day of heavy crude oil, and approximately 45,000 barrels per day of NGLs. It processes crude oil and NGLs that it receives from North American pipeline systems to produce gasoline, diesel and jet fuel along with NGLs and solv ents.

The Company’s Marketing group is focused ! on enhanc! ing the netback price of its production. It manages the transportation and marketing of crude oil for its upstream operations. It also manages the marketing of its natural gas, which is primarily sold to industrials, other producers and energy marketing companies.

Corporate and Eliminations

The segment includes inter-segment eliminations that relate to transactions that have been recorded at transfer prices based on current market prices, as well as unrealized intersegment profits in inventory. The Corporate and Eliminations segment also includes Cenovus costs for general and administrative and financing activities.

Advisors’ Opinion:

  • [By Robert Rapier]

    There are a number of quality Canadian E&P companies that are attractive at current prices. Among my favorites are Baytex Energy (NYSE: BTE, TSE: BTE), Cenovus Energy (NYSE: CVE, TSE: CVE) and Canadian Natural Resources (NYSE: CNQ, TSE: CNQ) I also like Peyto Exploration & Development (TSE: PEY, OTC: PEYUF) for aggressive investors. We have often discussed putting Peyto in one of the portfolios, but I would ideally like it a bit cheaper.

  • [By Holly LaFon]

    n addition to this new position, we got a trading opportunity in Cenovus (CVE), the Canadian oil sands company, and added it to the Global Value Fund and Global Value Fund II – Currency Unhedged. It had previously only been held in the Worldwide High Dividend Yield Value Fund. We also added to our positions in Banco Santander Brasil, Antofagasta, Bangkok Bank, Imperial Tobacco, and Unilever.From Tweedy Browne (Trades, Portfolio)’s first quarter 2014 letter to investors.Also check out: Tweedy Browne Undervalued Stocks Tweedy Browne Top Growth Companies Tweedy Browne High Yield stocks, and Stocks that Tweedy Browne keeps buying Currently 0.00/512345

    Rating: 0.0/5 (0 votes)

  • [By Robert Rapier]

    Whether KXL is approved is unlikely to have a big impact on any particular company. TransCanada would probably see the most significant share price movement, but the project isn’t a make-or-break for the company. Oil sands producers like Cenovus Energy (NYSE: CVE, TSE: CVE) have signed up to ship on KXL, and could see some share price movement as well. KXL would probably be the low-cost shipping option for Cenovus and other oil sands producers, but during my visit to Fort McMurray in November Cenovus emphasized that whether KXL is approved or not, the outcome would have no effect on its growth plans given the ready availability of alternatives.

Top Dow Dividend Stocks To Invest In Right Now: General Growth Properties Inc. (GGP)

General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls. General Growth Properties, Inc was founded in 1986 and is based in Chicago, Illinois.

Advisors’ Opinion:

  • [By Will Ashworth]

    REITs such as Simon Property Group (SPG) and General Growth Properties (GGP) have enterprise values that are 20 times EBITDA, while LTM stock putters along at slightly less than nine times EBITDA.

  • [By Michael Calia]

    General Growth Properties Inc.(GGP) said its fourth-quarter profit surged as it reported a higher mall-leased percentage and a bigger-than-expected increase in revenue.

Top Dow Dividend Stocks To Invest In Right Now: Forest Laboratories Inc (FRX)

Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician’s prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company’s principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer’s disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor ( SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.


In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback s ystem which, through a ‘colored control window’ and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.


Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.


As a result of its acquisition of Clinical Data, Inc. (Clinical Data) complet ed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.


In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.


Namenda (memantine HCl) is an N -methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer’s disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer’s type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.


Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).


Savella (milnacipran HCl) is the Company’s selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pa in and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.


In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.


Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.


Lexapro’s is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro’s (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.


Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also und ergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.


Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.

GRT 6005

In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.


In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.


In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA ag reed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.


RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.

Advisors’ Opinion:

  • [By David Williamson and Michael Douglass]

    The Science Translational Medicine journal recently published research about the generic antidepressant citalopram, which was developed by Forest Laboratories (NYSE: FRX  )  under the brand name Celexa, as a potential way to help slow down the development of Alzheimer’s disease.

  • [By Holly LaFon]

    The Fund’s average overweight position (20% versus 13%) and holdings in the Health Care sector (up 8% compared to up 6% for the S&P 500 sector) contributed to results. Forest Laboratories (FRX) (up 54%) agreed to be acquired by Actavis PLC (ACT). Merck (up 14%) also performed well.

  • [By Jake L’Ecuyer]

    Top Headline
    Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014.

  • [By Jake L’Ecuyer]

    Top Headline
    Forest Laboratories (NYSE: FRX) announced its plans to buy Furiex Pharmaceuticals (NASDAQ: FURX) for up to $1.46 billion. Forest will pay around $95 per share, or around $1.1 billion in cash. Forest Labs will also pay up to $30 per share, or around $360 million in a contingent value right. The deal is projected to close in the second or third quarter of 2014.